Abstract
Summary
Introduction
Tuberculosis is a major cause of illness and death worldwide, but despite 14.4
million prevalent cases, 9.2 million new cases and 1.7 million deaths in 2006,
the small and rapidly declining burden of disease in the seven major markets
has limited drug and vaccine development activities until recently.
Scope of this research
- An overview of the epidemiological trends in the seven major markets and
rest of world
- Discussion of the diagnostic methods for latent and active infection
- A review of current treatment regimens and antibiotic agents in
development for TB
- An assessment of vaccines in development for TB and the immunization
strategies being investigated
Research and analysis highlights
Drug developers and research foundations are trialling several novel vaccines
and therapeutic strategies for the prevention and treatment of TB.
Immunization approaches used include boosting the old BCG vaccine in order to
provide better, lasting protection; new vaccines to prevent adult pulmonary
TB; and immunotherapeutic vaccines.
In 2007 the global TB market was worth approximately $300 million, expanding
at a modest CAGR of 2.2% from 2004-2007. Given the low incidence of TB in the
seven major markets, they only accounted for around 40% of total sales; the
majority of revenues (60%) was achieved in the rest of world which includes
the majority of the high burden countries.
The most significant commercial opportunity exists in second line therapy,
since the drugs currently used in this setting suffer from greater toxicity
and less efficacy compared to first-line agents. Drugs that reduce the
duration of therapy and are active against drug resistant TB have a strong
chance of gaining significant commercial success.
Key reasons to purchase this research
- Understand the current TB market dynamics and future commercial
opportunities
- Examine unmet needs in the TB vaccines and antibiotics market and the
extent to which pipeline products are addressing these
- Identify the key vaccines and antibiotics in development for TB and their
likely positioning
| 
View Cart
